Trial Profile
Palivizumab (Synagis) Post-marketing Surveillance Cohort Study in Children < 24 Months of Age With Hemodynamically Significant Congenital Heart Disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Feb 2011
Price :
$35
*
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Abbott Laboratories
- 03 Mar 2010 New trial record